ERITROPOYETINA HUMANA RECOMBINANTE PDF

May 8, 2020 0 Comments

Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.

Author: Takus Tucage
Country: Comoros
Language: English (Spanish)
Genre: Life
Published (Last): 1 February 2012
Pages: 362
PDF File Size: 6.82 Mb
ePub File Size: 4.58 Mb
ISBN: 308-1-19369-980-6
Downloads: 30755
Price: Free* [*Free Regsitration Required]
Uploader: Vusho

Eritropoyetina Humana Recombinante Delta –

However, several authors reported no significant differences between anemia in BEN and other kidney diseases. Similar inter-individual differences were found in time needed to reach Epo C max.

Eur J Clin Pharmacol ; Although an impact of age on Epo elimination in our patients cannot be fully excluded, neither age nor other covariates that differed between the groups was found affect Epo elimination in the ANCOVA model.

Subscribe to free Drugs. Nephrol Dial Transplant eritopoyetina Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator C.

Eritropoyetina Humana Recombinante Delta

Available for Android and iOS devices. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. Erythropoietin Epo concentration was determined in all samples on the same day by chemiluminescent immunoassay for erythropoietin on an Immulite analyzer Siemens Healthcare Diagnostics. The aim of this reocmbinante was to compare the pharmacokinetics of beta-erythropoietin beta-Epo given subcutaneously to Eritropoyefina patients and patients with other kidney diseases non-BEN and to evaluate the factors influencing beta-Epo kinetics.

  COMPLETE REFERENCE J2EE JIM KEOGH PDF

When adjusted these differences remained statistically significant 0.

Eur J Haematol ; Pavlovic-Kentera V, Djukanovic Lj. J Am Soc Nephrol ;5: The prospective clinical study was performed eritropoyrtina to good clinical practice and in accordance with the Declaration of Helsinki in three clinical centers. However, the influence of ESA pharmacokinetics on hematopoietic response has not been sufficiently investigated. The significance of differences between mean values for groups was calculated using the Mann-Whitney U test and Student’s t-test.

Br J Eeritropoyetina Pharmacol ; Ingredient matches for Eritropoyetina Humana Recombinante Erythropoietin Erythropoietin is reported as an ingredient of Eritropoyetina Humana Recombinante in the following countries: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. Eritropoyetina Humana Recombinante Eritropoyetina Humana Recombinante may be available in the countries listed below.

Eritropoyetina Humana Recombinante

Our patients had iron reserves above the upper limit of normal and a similar proportion of subjects from each group used iron supplements. The predose plasma level of erythropoietin Epo was subtracted from all postdose levels.

Renal Injury from Drugs and Chemicals, third edition. Analysis of covariance ANCOVA was used to adjust these differences for patient characteristics that differed between groups: Faculty of Pharmacy, University of Belgrade, Serbia.

J Pharm Sci ; However, for protein and peptide drugs, dependency on recombinqnte tissue uptake, binding to intra- and extravascular proteins can substantially increase the value of Vd. Res Commun Mol Pathol Pharmacol ; Introduction Anemia was described as a characteristic of Balkan endemic nephropathy BEN in early reports on the disease, 1,2 so Danilovic 3 included it among the criteria for diagnosis.

  ATMEGA88PA DATASHEET PDF

Eritropoyetina Humana Recombinante –

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. N Engl J Med ; Djukanovic Lj, Radovanovic Z.

As previous studies showed that the kidneys contribute to Epo elimination in a very minor fashion 35 and residual kidney function in patients more than three years on dialysis is most often negligible, it is not expected that renal elimination of Epo could be of any influence. Endemic nephropathy in Bosnia. BEN is a slow progressive chronic kidney disease and patients who progress to end-stage renal disease usually start hemodialysis in the seventh decade of life.

The study involved 24 hemodialysis patients, 10 patients with BEN and 14 with other kidney diseases, selected from 96 patients 40 BEN and 56 others who met the inclusion criteria. Ciba Foundation Study Group No. Main characteristics of the patients ACEI: These findings need to be confirmed in a well-controlled study with a larger sample size in order to establish population pharmacokinetics of beta-Epo in BEN patients, to evaluate the effects of physiopathological factors on the disposition kinetics of beta-Epo and to find potential predictive factors for dosage individualization.

Kidney Int Suppl ;